Announcements Trials

Browse Landscape

Phase

Status

Recruiting 40 Active not recruiting 14 Not yet recruiting 10 Completed 4 Unknown 2 Enrolling by invitation 2 Withdrawn 1 Terminated 1

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Radiotherapy 91 pembrolizumab 88 Cyclophosphamide 84 Gemcitabine 70 Cisplatin 70 Magnetic Resonance Spectroscopy 65 Carboplatin 60 Radiosurgery 55 Paclitaxel 55 Nivolumab 48 Dexamethasone 45 Bevacizumab 42 Biopsy 41 Fluorouracil 39 durvalumab 37 Surveys and Questionnaires 36 Docetaxel 36 fludarabine 35 Doxorubicin 35 Radiation 33 Oxaliplatin 33 Capecitabine 33 Rituximab 32 fludarabine phosphate 31 Leucovorin 31 Cytarabine 30 Melphalan 29 Etoposide 28 Pemetrexed 27 Irinotecan 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × OTHER × sacituzumab govitecan × Clear all

NCT07134556 2026-05-01

ADJUNCT

MedSIR

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡